title: Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials.
abstract: BACKGROUND
  Selective serotonin reuptake inhibitors are increasingly used in the long-term treatment of depression. Much of the supporting evidence about the effects of these drugs comes from discontinuation trials, a variant of randomized controlled trials whose design is problematic to interpret. We conducted a systematic review to examine the efficacy and acceptability of long-term therapy with selective serotonin reuptake inhibitors relative to placebo in the treatment of unipolar depression.
  
  
  METHODS
  We identified placebo-controlled randomized trials with a treatment duration of at least 6 months by searching MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials to update a recently published systematic review. Efficacy was defined in terms of response to treatment (50% improvement in depression score relative to baseline) and remission (score of 7 or below on the Hamilton rating scale for depression). Key secondary outcomes included quality of life, return to work, need for additional treatment and self-harm. Overall acceptability was defined in terms of dropouts for any reason over a course of treatment.
  
  
  RESULTS
  Of the 2693 records identified initially, we included 6 randomized controlled trials that met our eligibility criteria. These studies had a moderate risk of bias, had assigned a total of 1299 participants with depression to either treatment or placebo and had followed both groups for 6-8 months. We observed statistically significant improvements in response to treatment (odds ratio [OR] 1.66, 95% confidence interval [CI] 1.12-2.48), but not in remission (OR 1.46, 95% CI 0.92-2.32) or acceptability (OR 0.87, 95% CI 0.67-1.14). The effects appeared greater among patients without comorbidities.
  
  
  CONCLUSIONS
  There is a lack of classic randomized controlled trials of serotonin reuptake inhibitors lasting more than 1 year for the treatment of depression. The results of our systematic review support current recommendations for 6-8 months of antidepressant treatment following initial recovery but provide no guidance for longer treatment.
authors.affiliation: Department of Psychiatry, University of Ottawa, Ottawa, Ont. deshauer1@sympatico.ca
authors.forename: Dorian
authors.initials: D
authors.lastname: Deshauer
authors.forename: David
authors.initials: D
authors.lastname: Moher
authors.forename: Dean
authors.initials: D
authors.lastname: Fergusson
authors.forename: Ester
authors.initials: E
authors.lastname: Moher
authors.forename: Margaret
authors.initials: M
authors.lastname: Sampson
authors.forename: Jeremy
authors.initials: J
authors.lastname: Grimshaw
mesh_terms: D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D017063:Outcome Assessment, Health Care; D010919:Placebos; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors